Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.
neoplasm of the genitourinary tract
Journal
Cold Spring Harbor molecular case studies
ISSN: 2373-2873
Titre abrégé: Cold Spring Harb Mol Case Stud
Pays: United States
ID NLM: 101660017
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
01
09
2021
accepted:
03
03
2022
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Sarcomatoid urothelial carcinoma (SUC) is a rare subtype of urothelial carcinoma (UC) that typically presents at an advanced stage compared to more common variants of UC. Locally advanced and metastatic UC have a poor long-term survival following progression on first-line platinum-based chemotherapy. Antibodies directed against the programmed cell death 1 protein (PD-1) or its ligand (PD-L1) are now approved to be used in these scenarios. The need for reliable biomarkers for treatment stratification is still under research. Here, we present a novel case report of the first Imaging Mass Cytometry (IMC) analysis done in SUC to investigate the immune cell repertoire and PD-L1 expression in a patient who presented with metastatic SUC and experienced a prolonged response to the anti-PD1 immune checkpoint inhibitor pembrolizumab after progression on first-line chemotherapy. This case report provides an important platform for translating these findings to a larger cohort of UC and UC variants.
Identifiants
pubmed: 35483877
pii: mcs.a006151
doi: 10.1101/mcs.a006151
pmc: PMC9059779
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
pembrolizumab
DPT0O3T46P
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022 Alnajar et al.; Published by Cold Spring Harbor Laboratory Press.
Références
Arch Pathol Lab Med. 2016 Jun;140(6):543-51
pubmed: 27031776
Clin Cancer Res. 2016 Jul 15;22(14):3630-42
pubmed: 26851185
Cancer Immunol Immunother. 2007 Aug;56(8):1173-82
pubmed: 17186290
Clin Exp Med. 2019 Nov;19(4):407-416
pubmed: 31407099
Nat Methods. 2019 Dec;16(12):1226-1232
pubmed: 31570887
Cancers (Basel). 2019 Dec 31;12(1):
pubmed: 31906050
Transl Oncol. 2021 Jan;14(1):100944
pubmed: 33190043
Sci Rep. 2019 Mar 26;9(1):5233
pubmed: 30914743
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Nature. 2021 May;593(7860):564-569
pubmed: 33780969
Genome Biol. 2006;7(10):R100
pubmed: 17076895
Sarcoma. 2010;2010:
pubmed: 20706685
Am J Surg Pathol. 2011 May;35(5):e34-46
pubmed: 21490442
Cancer Res. 2015 Jun 1;75(11):2139-45
pubmed: 25977340
J Urol. 2007 Dec;178(6):2302-6; discussion 2307
pubmed: 17936803
JAMA Oncol. 2018 Sep 1;4(9):1237-1244
pubmed: 29902298
Nat Methods. 2014 Apr;11(4):417-22
pubmed: 24584193
Oncologist. 2021 Nov;26(11):e1971-e1981
pubmed: 34286887
Eur J Cancer. 2006 Jan;42(1):50-4
pubmed: 16330205
Clin Cancer Res. 2016 Feb 1;22(3):609-20
pubmed: 26420858
Genome Biol. 2018 Feb 6;19(1):15
pubmed: 29409532
J Clin Oncol. 2012 Jan 10;30(2):191-9
pubmed: 22162575
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
Adv Exp Med Biol. 2014;816:183-96
pubmed: 24818724
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32221016
Ann Oncol. 2019 Jun 1;30(6):970-976
pubmed: 31050707
Sci Rep. 2020 Jan 29;10(1):1439
pubmed: 31996725
Eur Urol. 2020 Apr;77(4):548-556
pubmed: 31959546
Curr Urol Rep. 2018 Nov 7;19(12):109
pubmed: 30406502
Oncogene. 2010 Aug 26;29(34):4741-51
pubmed: 20531305